Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study

BMC Infectious Diseases

Ricardo AA Ximenes⁷  Alex A dos Santos²  Marcelo Costa⁸  Luis Claudio A Alencar³  Maria Luiza C Lima⁹  Deborah Crespo^1,11  Gabriela Coral⁴  Marília D Turchi⁵  Cynthia Braga⁹  Ulisses R Montarroyos⁷  Gerusa M Figueiredo^1,10  Regina Maria A Cardoso^1,10  Airton T Stein⁴  Edgar Merchan-Hamman¹  Regina C Moreira^1,12  Celina MT Martelli⁷  Leila MMB Pereira⁶ 

[1] Universidade de Brasília, Faculdade de Ciências da Saúde, Departamento de Saúde Coletiva. DSC - Faculdade de Saúde, Campus Universitário Darcy Ribeiro – Asa Norte, CEP: 70910-900, Brasília, DF, Brazil;Instituto Bioestatístico –IBCT, Rua Bernal do Couto, 1311, Umarizal, CEP: 67150-050, Belem, PA, Brazil;Universidade de Pernambuco, Faculdade de Ciências Médicas de Pernambuco, Hospital Universitário Oswaldo Cruz, Rua Arnóbio Marques, 310, Santo Amaro, CEP: 50100-130, Recife, PE, Brazil;Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Sarmento Leite, 245, Bom Fim, CEP: 90050-170, Porto Alegre, RS, Brazil;Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Publica, Departamento de Saúde Coletiva, Rua Delenda Rezende de Mello, s/n, sala 405, Setor Universitário, CEP: 74605050, Goiânia, GO, Brazil;Instituto do Fígado de Pernambuco, Rua Aluísio Azevedo, 209, Santo Amaro, 50.100-130, Recife, PE, Brazil;Universidade Federal de Pernambuco, Departamento de Medicina Tropical, Av. Prof. Moraes Rego, s/n, Cidade Universitária, CEP: 50670-420, Recife, PE, Brazil;Hospital de Base do DF, Area Especial, Asa Sul, CEP:70.335-900, Brasília, DF, Brazil;Fundação Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhães, Av Moraes Rego, s/n, Cidade Universitária, CEP: 50000-230, Recife, PE, Brazil;Departamento de Epidemiologia, Universidade de São Paulo, Faculdade de Saúde Pública, Avenida Dr. Arnaldo 715, Cerqueira Cesar, 01246-904, São Paulo, SP, Brazil;Secretaria de Saúde Pública do Estado do Pará, Av. Conselheiro Furtado, 1597, CEP 66040-100, Belém, PA, Brazil;Instituto Adolfo Lutz, Av. Dr. Arnaldo, nº 355, Cerqueira Cézar, CEP: 01246-902, Capital, SP, Brazil

关键词: Risk factors;    Cross sectional study;    Genotype;    Prevalence;    Hepatitis C virus;   

Others  :  1158451
DOI  :  10.1186/1471-2334-13-60

 received in 2012-08-06, accepted in 2013-01-11,  发布年份 2013

【 摘 要 】

Background

Hepatitis C chronic liver disease is a major cause of liver transplant in developed countries. This article reports the first nationwide population-based survey conducted to estimate the seroprevalence of HCV antibodies and associated risk factors in the urban population of Brazil.

Methods

The cross sectional study was conducted in all Brazilian macro-regions from 2005 to 2009, as a stratified multistage cluster sample of 19,503 inhabitants aged between 10 and 69 years, representing individuals living in all 26 State capitals and the Federal District. Hepatitis C antibodies were detected by a third-generation enzyme immunoassay. Seropositive individuals were retested by Polymerase Chain Reaction and genotyped. Adjusted prevalence was estimated by macro-regions. Potential risk factors associated with HCV infection were assessed by calculating the crude and adjusted odds ratios, 95% confidence intervals (95% CI) and p values. Population attributable risk was estimated for multiple factors using a case–control approach.

Results

The overall weighted prevalence of hepatitis C antibodies was 1.38% (95% CI: 1.12%–1.64%). Prevalence of infection increased in older groups but was similar for both sexes. The multivariate model showed the following to be predictors of HCV infection: age, injected drug use (OR = 6.65), sniffed drug use (OR = 2.59), hospitalization (OR = 1.90), groups socially deprived by the lack of sewage disposal (OR = 2.53), and injection with glass syringe (OR = 1.52, with a borderline p value). The genotypes 1 (subtypes 1a, 1b), 2b and 3a were identified. The estimated population attributable risk for the ensemble of risk factors was 40%. Approximately 1.3 million individuals would be expected to be anti-HCV-positive in the country.

Conclusions

The large estimated absolute numbers of infected individuals reveals the burden of the disease in the near future, giving rise to costs for the health care system and society at large. The known risk factors explain less than 50% of the infected cases, limiting the prevention strategies. Our findings regarding risk behaviors associated with HCV infection showed that there is still room for improving strategies for reducing transmission among drug users and nosocomial infection, as well as a need for specific prevention and control strategies targeting individuals living in poverty.

【 授权许可】

   
2013 Pereira et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5(9):558-567.
• [2]Te HS, Jensen DM: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14(1):1-21. vii
• [3]Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341(8):556-562.
• [4]Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, et al.: Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis 2008, 46(12):1852-1858.
• [5]Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144(10):705-714.
• [6]McQuillan GM, Kruszon-Moran D, Denniston MM, Hirsch R: Viral Hepatitis. In NCHS Data Brief. Prevention CfDCa, vol. 27. Hyattsville, MD: National Center for Health Statistics; 2010.
• [7]Daniels D, Grytdal S, Wasley A: Surveillance for acute viral hepatitis - United States, 2007. Morbidity and mortality weekly report Surveillance summaries (Washington, DC: 2002) 2009, 58(3):1-27.
• [8]Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, Warszawski J, Steinmetz J, Coste D, Meyer JF, et al.: Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010, 82(4):546-555.
• [9]Kershenobich D, Razavi HA, Sanchez-Avila JF, Bessone F, Coelho HS, Dagher L, Goncales FL, Quiroz JF, Rodriguez-Perez F, Rosado B, et al.: Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011, 31(Suppl 2):18-29.
• [10]Brazilian Ministry of Health: Boletim Epidemiológico das Hepatites Virais 2010. Brasília: Brazilian Ministry of Health; 2010.
• [11]Foccacia R, da Conceição O, Sette H, Sabino E, Bassit L, Nitrini D, Lomar A, Lorenço R, Vieira de Souza F, Kiffer C, et al.: Estimated Prevalence of Viral Hepatitis in the General Population of the Municipality of São Paulo, Measured by a Serologic Survey of a Stratified, Randomized and Residence-Based Population. Braz J Infect Dis 1998, 2(6):269-284.
• [12]Zarife MA, Silva LK, Silva MB, Lopes GB, Barreto ML, Teixeira Mda G, Dourado I, Reis MG: Prevalence of hepatitis C virus infection in north-eastern Brazil: a population-based study. Trans R Soc Trop Med Hyg 2006, 100(7):663-668.
• [13]Ivantes CA, Silva D, Messias-Reason I: High prevalence of hepatitis C associated with familial history of hepatitis in a small town of south Brazil: efficiency of the rapid test for epidemiological survey. Braz J Infect Dis 2010, 14(5):483-488.
• [14]Carneiro MA, Martins RM, Teles SA, Silva SA, Lopes CL, Cardoso DD, Vanderborght BO, Yoshida CF: Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz 2001, 96(6):765-769.
• [15]Perone C, Del Castillo DM, Pereira GL, Carvalho Nde O, Januario JN, Teixeira R: High prevalence of genotype 1 in individuals with hepatitis C in Belo Horizonte, MG. Rev Soc Bras Med Trop 2008, 41(3):238-242.
• [16]Lopes CL, Teles SA, Espirito-Santo MP, Lampe E, Rodrigues FP, Motta-Castro AR, Marinho TA, Reis NR, Silva AM, Martins RM: Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil. Rev Saude Publica 2009, 43(Suppl 1):43-50.
• [17]Nishioka Sde A, Gyorkos TW, MacLean JD: Tattoos and transfusion-transmitted disease risk: implications for the screening of blood donors in Brazil. Braz J Infect Dis 2002, 6(4):172-180.
• [18]Freitas SZ, da Cunha RV, Martins RM, Teles SA, Ibanhes ML, Motta-Castro AR: Prevalence, genotypes and risk factors associated with hepatitis C virus infection in hemodialysis patients in Campo Grande, MS, Brazil. Mem Inst Oswaldo Cruz 2008, 103(4):405-408.
• [19]Campiotto SPJ, Carrilho FJ, Da Silva LC SF, Spinelli V, et al.: Geographic distribution of hepatitis C virus genotypes in Brazil. Brazilian Journal of Medicine and Biology Research 2005, 38:41-49.
• [20]Ximenes RAA, Martelli CMT, Merchán-Hamann E, Montarroyos UR, Braga MC, de Lima MLC, Cardoso MRA, Turchi MD, Costa MA, de Alencar LCA, et al.: Multilevel analysis of hepatitis A infection in children and adolescents: a household survey in the Northeast and Central-west regions of Brazil. Int J Epidemiol 2008, 37:852-861.
• [21]Pereira LM, Martelli CM, Merchan-Hamann E, Montarroyos UR, Braga MC, de Lima ML, Cardoso MR, Turchi MD, Costa MA, de Alencar LC, et al.: Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. AmJTrop Med Hyg 2009, 81(2):240-247.
• [22]Ximenes RA, Pereira LM, Martelli CM, Merchan-Hamann E, Stein AT, Figueiredo GM, Braga MC, Montarroyos UR, Brasil LM, Turchi MD, et al.: Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. Cad Saude Publica 2010, 26(9):1693-1704.
• [23]Fonseca JC: Epidemiologia da infecção pelo vírus da hepatite C no Brasil. Gastroenterologia Endoscopia Digestiva 1999, 18(supl 1):S3-S8.
• [24]The Brazilian Institute of Geography and Statistics (IBGE): Demographic Census 2000: characteristics of the population and households, results from the population universe. Available from: http://www.ibge.gov.br/home/estatistica/populacao/censo2000/default.shtm webcite.
• [25]Rabe-Hesketh S, Skrondal A: Multilevel and longitudinal modeling using Stata. College Station, Texas: Stata Press; 2005.
• [26]Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C: Estimating the population attributable risk for multiple risk factors using case–control data. Am J Epidemiol 1985, 122(5):904-914.
• [27]Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, Roudot-Thoraval F, Hillon P, Silvain C, Dhumeaux D, Desenclos JC: The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010, 17(6):435-443.
• [28]Nascimento MC, Mayaud P, Sabino EC, Torres KL, Franceschi S: Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. J Med Virol 2008, 80(1):53-57.
• [29]Victora CG, Barreto ML, do Carmo Leal M, Monteiro CA, Schmidt MI, Paim J, Bastos FI, Almeida C, Bahia L, Travassos C, et al.: Health conditions and health-policy innovations in Brazil: the way forward. Lancet 2011, 377(9782):2042-2053.
• [30]Rantala M, van de Laar MJ: Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 2008, 13(21):pii=18880. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18880 webcite.
• [31]Irving WL, Salmon D, Boucher C, Hoepelman IM: Acute hepatitis C virus infection. Euro Surveill 2008, 13(21):pii=18879. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18879 webcite.
• [32]Alter MJ: Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13(17):2436-2441.
• [33]Duailibi LB, Ribeiro M, Ronaldo L: Profile of cocaine and crack users in Brazil. Cad Saude Publica 2008, 24(Supl 4):S545-S557.
• [34]Fonseca AM: Comparison between two household surveys on psychotropic drug use in Brazil: 2001 and 2004. Ciencia e Saude Coletiva 2010, 15(3):663-670.
• [35]Ferreira Filho OF, Turchi MD, Laranjeira R, Castelo A: Perfil sociodemografico e de padrões de uso entre dependentes de cocaína hospitalizados. Ver Saude Publica 2003, 37(6):751-759.
• [36]Schlesselmann JJ: Case–control studies. Design, conduct, analysis. Oxford: Oxford University Press; 1982.
• [37]Micallef JM, Kaldor JM, Dore GJ: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006, 13(1):34-41.
• [38]Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461(7265):798-801.
• [39]Lunge VR, da Rocha DB, Béria JU, Tietzmann DC, Stein AT, Simon D: IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population. AIDS Res Hum Retroviruses 2012, 28(2):215-219.
• [40]Oliveira ML, Bastos FI, Telles PR, Hacker Mde A, Oliveira SA, Miguel JC, Yoshida CF: Epidemiological and genetic analyses of Hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil. J Clin Virol 2009, 44(3):200-206.
• [41]Wong JB, McQuillan GM, McHutchison JG, Poynard T: Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90(10):1562-1569.
• [42]King LA, Le Strat Y, Meffre C, Delarocque-Astagneau E, Desenclos JC: Assessment and proposal of a new combination of screening criteria for hepatitis C in France. Eur J Public Health 2009, 19(5):527-533.